CollPlant shares fall 34.79% premarket after announcing $2.0M registered direct offering and warrant issuance.

CollPlant Biotechnologies (NASDAQ: CLGN) fell 34.79% in premarket trading after announcing a registered direct offering and concurrent private placement to raise approximately $2.0 million through the issuance of 1.6 million ordinary shares and warrants. The financing, which includes dilutive unregistered warrants exercisable at $1.25 per share, was executed to fund general corporate purposes, including working capital and R&D. The move likely triggered a sell-off as investors reacted to the equity issuance, which signals potential share dilution and could raise concerns about the company’s financial health or growth prospects. The offering’s structure, involving both public and private placements, may also indicate limited demand for CollPlant’s technology in its core regenerative medicine and aesthetics markets, exacerbating bearish sentiment.